August 5, 2026
9:44 pm

COPD and Selling a Life Insurance Policy (2026 Guide)

Chronic obstructive pulmonary disease does not prevent you from selling a life insurance policy — it is one of the conditions the secondary market most often accepts, and moderate-to-severe COPD generally increases what a qualifying policy is worth. The reason is mechanical rather than sentimental. Life settlement buyers price a policy by estimating how long they will pay premiums before the death benefit is collected, and COPD is progressive, staged with objective spirometry, and thoroughly documented in pulmonology records.

That said, a diagnosis alone does not create value. The policy has to clear its own gate: a death benefit of roughly $100,000 or more, a permanent or convertible product rather than expiring term, a cost of insurance that is not runaway, and no crippling loan balance. Plenty of people with advanced COPD hold policies the market will not touch, and plenty of people with mild COPD hold excellent policies that simply are not worth selling yet.

This guide covers what underwriters read in a COPD file, how the options rank, and when keeping or surrendering is the honest answer. Pine Lake Life Solutions provides education and a free policy review, not medical, legal, or tax advice.

In This Article

What a Life Expectancy Underwriter Reads in a COPD File
Why COPD Improves Market Value But Not Cash Value
The Policy Screen Is Separate From the Health Screen
Every Alternative Side by Side
When Selling Is Not the Right Answer
Protecting the Policy While You Decide
Timing, Paperwork, and Getting a Straight Answer
Frequently Asked Questions

COPD and Selling a Life Insurance Policy (2026 Guide)

What a Life Expectancy Underwriter Reads in a COPD File

The core measurement is spirometry, specifically FEV1 as a percentage of predicted value, which drives the GOLD staging system used worldwide — Stage 1 mild through Stage 4 very severe. Underwriters also look at the GOLD ABE assessment grouping that combines symptom burden with exacerbation history, because a patient with frequent exacerbations carries a materially different risk profile from a stable patient at the same FEV1.

Beyond spirometry, the file is read for supplemental oxygen use and how many hours per day, hospitalizations or emergency visits for exacerbations in the past 12 to 24 months, body mass index and unintentional weight loss, six-minute walk distance where recorded, continued smoking versus documented cessation, and comorbidities. Cardiac disease, pulmonary hypertension, and diabetes alongside COPD shorten estimates considerably. Right heart involvement, or cor pulmonale, is a significant marker.

The practical lesson is that record quality drives pricing. A file with recent pulmonary function tests, current medication lists, and a clear exacerbation history yields a defensible estimate. A sparse file yields a conservative one, which usually means a lower offer or no offer.

Why COPD Improves Market Value But Not Cash Value

Two different numbers move in opposite directions here. Cash surrender value is what your carrier owes you if you quit the contract; it is set by the policy’s mechanics and is completely indifferent to your health. Market value is what an investor would pay to take over the contract, and it responds directly to projected life expectancy.

So a person with GOLD Stage 3 COPD, on daily supplemental oxygen, holding a $400,000 universal life policy, may find that the policy is worth several times its surrender value in the secondary market while the carrier’s surrender check has not budged. The federal U.S. Government Accountability Office study of the market (GAO-10-775) found sellers typically received roughly 10% to 35% of face value, several multiples of what surrender would have paid — commonly summarized as 4 to 8 times cash surrender value. See what cash surrender value actually is for the distinction in detail.

The Policy Screen Is Separate From the Health Screen

Health can be perfect for the market and the policy still fail. The screens that matter: death benefit of about $100,000 or more, because underwriting, escrow, and legal costs are largely fixed; a permanent product — universal life, guaranteed universal life, whole life, or indexed universal life — or a term policy with an unexpired conversion right; an in-force period beyond the two-year contestability window; and an outstanding loan balance small enough that it does not consume the offer, since loans come off any purchase price dollar for dollar.

Final expense and burial policies, typically issued between $5,000 and $25,000, are almost never large enough to settle regardless of the insured’s health. That is a straightforward fact worth knowing before anyone spends time on it. Our page on minimum policy size explains the economics.

COPD Factor	Source in the Record	Typical Effect on Offers
GOLD stage (FEV1 % predicted)	Spirometry / pulmonary function test	Higher stage raises value
Supplemental oxygen hours per day	DME orders, pulmonology notes	Continuous oxygen raises value
Exacerbations requiring admission	Hospital records, past 12-24 months	Frequent admissions raise value
Weight loss / low BMI	Office visit vitals	Unintentional loss raises value
Continued smoking	Social history	Generally raises value
Cardiac or pulmonary hypertension comorbidity	Cardiology, echo reports	Materially raises value
Sparse or outdated records	Missing PFTs	Lower offers or no offer

The Policy Screen Is Separate From the Health Screen

Every Alternative Side by Side

Keep and keep paying. Right whenever a spouse or dependent will need the benefit and the premium is manageable. Death proceeds are generally received income-tax-free by beneficiaries under Internal Revenue Code section 101(a)(1); a settlement converts that into partly taxable cash today at a fraction of face value.

Chronic illness or accelerated death benefit rider. Read the rider schedule before anything else. Chronic illness riders generally require inability to perform two of six activities of daily living, or severe cognitive impairment, certified by a licensed health practitioner. Advanced COPD with oxygen dependence sometimes meets that bar. Qualifying payments are generally excluded from income under Internal Revenue Code section 101(g), subject to statutory conditions and per-diem limits for chronically ill insureds — confirm the current-year limit with your tax advisor.

Policy loan or withdrawal. Keeps the contract alive and provides cash. Interest accrues, and an unpaid loan reduces the benefit. Dangerous on a universal life policy where rising cost of insurance is already draining account value.

Reduced paid-up insurance. On a permanent policy, ends premiums and preserves a smaller, fully paid death benefit. The best answer when the pressure is premium cost rather than a need for cash.

1035 exchange. Internal Revenue Code section 1035 permits a tax-free exchange into another life contract, an annuity, or a qualified long-term care contract. Rarely advantageous for someone with progressive lung disease, since it typically means giving up coverage priced when you were healthier.

Surrender. Simple and fast, but usually the lowest payout available for a policy the market would value.

Life settlement. A lump sum today, appropriate when coverage is no longer needed, oxygen and care costs are mounting, or the premium is competing with living expenses.

When Selling Is Not the Right Answer

Be honest about the cases where the market is the wrong door. If COPD is GOLD Stage 1 or 2, well controlled, with no exacerbations and no oxygen, projected life expectancy remains long and offers will be small or absent — keeping the policy is better. If a surviving spouse has limited retirement income and the death benefit is the plan, do not trade it for a partial lump sum. If the policy is under roughly $100,000, the market will not engage and the carrier is your only counterparty.

There is also a timing consideration. Because value rises as the disease progresses, some households benefit from keeping the policy in force now and revisiting later, provided the premium is affordable and the policy is not at risk of lapse. That is not a promise of a better offer later; it is a reason not to rush. Read when a life settlement is a bad idea before you start.

Protecting the Policy While You Decide

The worst outcome in this whole space is an unintended lapse. Most policies carry a grace period, commonly 31 days, and many permit reinstatement — but reinstatement usually requires evidence of insurability, which advanced COPD can make impossible. Once the policy lapses, its market value goes to zero.

If premiums are a strain while you evaluate, call the carrier and ask about switching to monthly billing, applying dividends or cash value toward premiums, or invoking a waiver-of-premium rider if one exists. Request an in-force illustration at the same time; it projects future premiums and account values and is the document buyers price from. Our explainer on the in-force illustration covers what to ask for.

Timing, Paperwork, and Getting a Straight Answer

A full transaction runs roughly 60 to 120 days. You will sign a HIPAA authorization — under 45 CFR 164.508 it must state an expiration date and your right to revoke it — so underwriters can obtain pulmonology and hospital records. One or two independent life expectancy reports are typical, and they often disagree. Funds should be held by an independent escrow agent until the carrier records the ownership change, and most states provide a rescission window after funding, commonly 15 to 30 days; confirm your state’s rule.

To learn where you stand, send the policy cover page showing insurer, policy number, face amount, and issue date. The review is free and carries no obligation, and if the answer is that the policy is too small or the disease too early, you will hear it directly. Call (305) 209-7183 with questions. This page is educational only and is not medical, legal, or tax advice.

Frequently Asked Questions

Can I sell a life insurance policy if I have COPD?

Yes, assuming the policy itself qualifies. COPD is among the conditions the secondary market accepts most readily because it is progressive and objectively staged by spirometry. Moderate to severe disease generally improves pricing, while mild, well-controlled COPD often produces small offers or none.

What medical records will be requested?

Typically pulmonology and primary care notes, spirometry or pulmonary function tests, hospitalization records for exacerbations, current medication and oxygen orders, and documentation of comorbidities. You will sign a HIPAA authorization that must state an expiration date and your right to revoke it under 45 CFR 164.508.

Does being on oxygen change the offer?

It is a meaningful data point. Continuous or near-continuous supplemental oxygen generally signals more advanced disease and shortens projected life expectancy estimates, which raises what a buyer can pay. The number of hours per day and the duration of oxygen use both matter.

How much could my policy be worth?

The federal GAO study (GAO-10-775) found sellers typically received roughly 10% to 35% of face value, often several times surrender value. Where a specific COPD case lands depends on stage, exacerbation history, comorbidities, the death benefit, and the cost of keeping the policy in force.

My policy is a $15,000 final expense policy. Can I sell it?

Almost certainly not. Final expense and burial policies are typically issued between $5,000 and $25,000, far below the roughly $100,000 practical floor for a settlement, because fixed transaction costs make small policies uneconomic. Keeping the policy or checking any available rider is the more realistic path.

Should I wait for the disease to progress before selling?

Sometimes waiting produces a better offer, since value rises as life expectancy shortens, but that only works if the premium stays affordable and the policy never lapses. A lapse destroys the value entirely. Weigh cash needs today against a possible improvement later with your own advisors.

How long does the process take?

Roughly 60 to 120 days from initial review to funded payment, with medical record retrieval and life expectancy underwriting typically taking the longest. Most states provide a rescission window after funding, commonly 15 to 30 days, during which you can return the proceeds.

Find out what your policy is worth — free, confidential, no obligation.

A 15-minute educational review covers your eligibility, every alternative, and a realistic view of what each path would net you.

Call (305) 209-7183 · Request a review online →

Table of Contents